iNOS is a key mediator of anti-PD-1 melanoma therapy response - Top-Institutions - MDSpire

iNOS is a key mediator of anti-PD-1 melanoma therapy response

  • By

  • Quang Tam Nguyen

  • Youngchul Kim

  • Thi Hong Nga Le

  • Saurabh Garg

  • Vishanna Balkaran

  • Trisha Bhathivi

  • Alejandra Chamizo

  • Christopher W. Dukes

  • Kimberly Ward

  • Andrew S. Brohl

  • Lilit Karapetyan

  • Nikhil I. Khushalani

  • Zeynep Eroglu

  • Ahmad A. Tarhini

  • James J. Mulé

  • Joseph Markowitz

  • June 22, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Yale Cancer Center
    Yale Cancer Center

    New Haven, Connecticut

    Key Differentiators

    • Oncology

  • #3

    University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

    Key Differentiators

    • Oncology

  • #4

    Institut Gustave Roussy
    Institut Gustave Roussy

    Villejuif, France

    Key Differentiators

    • Oncology

  • #5

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

Original Source(s)

iNOS is a key mediator of anti-PD-1 melanoma therapy response

  • by Quang Tam Nguyen, Youngchul Kim, Thi Hong Nga Le, Saurabh Garg, Vishanna Balkaran, Trisha Bhathivi, Alejandra Chamizo, Christopher W. Dukes, Kimberly Ward, Andrew S. Brohl, Lilit Karapetyan, Nikhil I. Khushalani, Zeynep Eroglu, Ahmad A. Tarhini, James J. Mulé, Joseph Markowitz

  • June 22, 2026

Related Content

Privacy-Conscious Skin Cancer Diagnosis through Federated Learning and Deep Neural Networks

Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma

Frozen melanoma tissues yield extracellular vesicles with preserved diagnostic and immunogenic properties